University Hospitals Birmingham NHS Foundation Trust

Reports

Status Drug name NICE TAs Comments
Status: Red Ralititrexed injection

Hospital use only

Status: Green Ramipril capsules

Ramipril (as capsules) has the most robust evidence base and is considered to be the first line agent of choice.

Status: Amber Ranolazine M/R

Consultant to initiate and stabilise patient before GP takes over prescribing

Status: Amber Rasagiline

ESCA

Status: Red Reflectant (Dundee) sunscreens

Unlicensed specials

Status: Red Regorafenib (Stivarga®)

For hospital use only

Status: Amber Relugolix/Estradiol/Norethisterone (Ryeqo®)
Status: Green Renavit

Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis. 

Status: Green Repevax

Supported with PGD

Status: Red Resilizumab (Cinqaero®)

Hospital only

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.

Building healthier lives
Back to top